Stanford Finds 12-Amino-Acid BRP That Cuts Food Intake 50% as Ozempic-Like Side Effects Fade
Updated
Updated · ScienceDaily · Jul 24
Stanford Finds 12-Amino-Acid BRP That Cuts Food Intake 50% as Ozempic-Like Side Effects Fade
1 articles · Updated · ScienceDaily · Jul 24
Summary
Animal tests showed BRP—a naturally occurring peptide found by Stanford researchers with AI—cut food intake by up to 50% in mice and minipigs and drove weight loss in obese mice.
A 14-day course left obese mice 3 grams lighter, almost entirely from fat, while control mice gained about 3 grams; treated animals also showed better glucose and insulin tolerance.
Peptide Predictor scanned 20,000 human protein-coding genes, narrowed candidates to 373 prohormones and 2,683 possible peptides, then helped identify BRP after cell tests showed a 10-fold neuron-activity increase.
BRP appears to act mainly in the hypothalamus rather than broadly across the gut, pancreas and other tissues, which may explain why researchers did not see nausea-like responses, constipation or major muscle loss in animals.
Human proof is still pending: the team is identifying BRP's receptor and trying to extend the short-lived peptide's duration, while a company co-founded by senior author Katrin Svensson plans clinical trials.
Could a newly discovered AI-predicted brain peptide finally replace Ozempic by melting fat without the dreaded nausea and muscle loss?
If this natural peptide safely mimics semaglutide in animals, how soon could human trials disrupt the billion-dollar weight-loss industry?
What secret hunger-killing pathways are hiding in our DNA that this new AI algorithm just unlocked for future weight loss?
BRP Peptide vs. GLP-1: Stanford’s 2026 AI Breakthrough Promises Side-Effect-Free Weight Loss and Market Disruption
Overview
Stanford Medicine’s July 2026 discovery of the BRP peptide, powered by advanced AI platforms, marks a major shift in weight-loss drug development. Unlike GLP-1 drugs, which act throughout the body and often cause severe side effects like nausea and gastroparesis, BRP works only in the hypothalamus, directly activating POMC neurons to suppress hunger and boost metabolism without triggering gastrointestinal distress. This targeted action avoids the start-and-stop cycle and weight regain seen with GLP-1s. As BRP operates through a novel pathway, it offers hope for patients who do not respond to current drugs, but its market entry could disrupt healthcare budgets and raise new ethical questions about access and affordability.